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Abstract
Na+ channel blockers flecainide and quinidine can increase propensity to ventricular tachy-
arrhythmia, whereas lidocaine and mexiletine are recognized as safe antiarrhythmics. Clini-
cally, ventricular fibrillation is often precipitated by transient tachycardia that reduces action
potential duration, suggesting that a critical shortening of the excitation wavelength (EW)
may contribute to the arrhythmic substrate. This study examined whether different INa block-
ers can produce contrasting effects on the rate adaptation of the EW, which would explain
the difference in their safety profile. In perfused guinea-pig hearts, effective refractory peri-
ods (ERP), conduction times, and EW values were determined over a wide range of cardiac
pacing intervals. All INa blockers tested were found to flatten the slope of ERP restitution,
indicating antiarrhythmic tendency. However, with flecainide and quinidine, the beneficial
changes in ERP were reversed owing to the use-dependent conduction slowing, thereby
leading to significantly steepened restitution of the EW. In contrast, lidocaine and mexiletine
had no effect on ventricular conduction, and therefore reduced the slope of the EW restitu-
tion, as expected from their effect on ERP. These findings suggest that the slope of the EW
restitution is an important electrophysiological determinant which can discriminate INa block-
ers with proarrhythmic and antiarrhythmic profile.
Introduction
Na+ channel blockers are class I antiarrhythmic agents which may suppress tachyarrhythmia
by prolonging the effective refractory period (ERP) and therefore eliminating the excitable gap
in re-entrant circuit. Nevertheless, the clinical experience in using these agents to control car-
diac arrhythmia has been challenged by observations on ventricular proarrhythmic responses
that may occur in 1–8% of patients receiving Na+ channel blocker therapy [1–2]. In this regard,
the Cardiac Arrhythmia Supression Trial (CAST) has demonstrated that administration of fle-
cainide, class Ic agent, to patients with healed myocardial infarction was associated with a
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2.5-fold greater risk of sudden arrhythmic death as compared to patients treated with placebo
[3]. Flecainide is therefore currently contraindicated in patients with structural heart disease.
Quinidine, class Ia agent previously used to restore sinus rhythm in atrial fibrillation, has been
shown to facilitate the life-threatening ventricular tachyarrhythmia and increase cardiac mor-
tality rates over long-term follow-up [4–5]. Accordingly, quinidine is not generally used now
for antiarrhythmic therapies, excepting some special clinical conditions (e.g. Brugada syn-
drome). In contrast, class Ib Na+ channel blockers such as lidocaine and mexiletine are
thought to be safe antiarrhythmics [6–7]. The mechanisms contributing to the striking differ-
ence in arrhythmic safety profile between different subgroups of class I agents remain incom-
pletely understood. It is noteworthy, however, that in contrast to class Ia and Ic agents which
slowly dissociate from the Na+ channel and hence significantly delay ventricular conduction,
lidocaine and mexiletine exhibit fast kinetics of the INa blockade, and produce little or no
change in conduction velocity in non-ischemic hearts [8–9].
Ambulatory ECG monitoring in victims of sudden death suggests that fatal cardiac arrest
is typically preceded by abrupt heart rate acceleration leading to the reduction in ventricular
action potential duration (APD) [10–11]. These observations imply that ventricular fibrilla-
tion (VF) may be precipitated by the critical shortening of the excitation wavelength, the
distance traveled by the activation front during the duration of the refractory period. Upon
an excessive shortening of the excitation wavelength, the area of depolarized cells could be
reduced to such an extent that the available current strength can become insufficient in
order to depolarize downstream myocytes. This would translate to the source-to-sink mis-
match and cause conduction failure [12–13]. The localized conduction block then can pro-
voke fragmentation of the propagating wavefront, thus leading to highly disorganized
electrical activation, a hallmark of VF. In support of this mechanism, an increase in the
slope of APD rate adaptation (the electrical restitution) has been demonstrated to increase
the propensity to develop VF, whereas flattening the restitution slope was proved to be anti-
arrhythmic [14–15].
These considerations suggest that drug-induced changes in the rate adaptation of the car-
diac excitation wavelength can be critical for understanding the difference in arrhythmic safety
profile among different subgroups of the Na+ channel blockers. The present study, therefore,
was designed to test the hypothesis that the excitation wavelength restitution can be steepened
by flecainide and quinidine, whereas lidocaine and mexiletine can reduce the electrical restitu-
tion slope. The hypothesis was proposed by considering the following arguments. The ventric-
ular excitation wavelength can be found as a product of effective refractory period (ERP) and
conduction velocity. Because an increase in cardiac activation rate leaves less diastolic time for
INa recovery from drug-induced block, class I agent effects on ERP and ventricular conduction
are likely to be use-dependent [8–9], i.e. more prominent at the short as compared to the long
diastolic intervals. The use-dependent prolongation of refractoriness by Na+ channel blocker
would then contribute to flattening the ERP restitution, indicating the antiarrhythmic ten-
dency. With class Ib agents (lidocaine and mexiletine), this change may prevent an excessive
shortening of the excitation wavelength upon heart rate acceleration, and therefore eliminate
the substrate for VF. In contrast, with class Ia (quinidine) and Ic (flecainide) agents, the benefi-
cial changes in ERP are likely to be eliminated owing to the marked conduction slowing at
short diastolic intervals, an effect which can facilitate proarrhythmia via the mechanisms
related to increased steepness of the excitation wavelength restitution. In the present study,
these possibilities were examined by assessing the rate adaptation of ERP, ventricular conduc-
tion times, and the excitation wavelength in perfused guinea-pig hearts upon infusion of flecai-
nide, quinidine, lidocaine and mexiletine.
Na+ channel blockers and excitation wavelength
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Materials and methods
This study complies with the European Community Guidelines for the Care and Use of Exper-
imental Animals, and was approved by the Animal Ethics Screening Committee of the Panum
Institute (clearance number: 2010/561-1799).
Isolated, langendorff-perfused heart preparations
The experiments on isolated, perfused hearts were performed as described previously [16–17].
Female Dunkin-Hartley guinea-pigs weighing 400–500 g were anesthetized with sodium pento-
barbital (50 mg/kg i.p.) and anticoagulated with heparin (1000 IU/kg i.p.). The chest was opened,
the hearts were immediately excised, mounted on a Langendorff perfusion set-up (Hugo Sachs
Elektronik-Harvard Apparatus GmbH, March-Hugstetten, Germany) and perfused via the aorta
at a constant flow (15 ml/min) with carefully filtered, warmed physiological saline solution satu-
rated with 95%O2 and 5%CO2. The perfusion solution contained (in mM) 118.0 NaCl; 4.7 KCl;
2.5 CaCl2; 25 NaHCO3; 1.2 KH2PO4; 1.2 MgSO4; and 10.0 glucose, and had a pH of 7.4. The aor-
tic perfusion pressure (65–70 mm Hg) was measured with a ISOTEC pressure transducer and
the coronary flow rate was determined using an ultrasonic flowmeter probe (Transonic Systems
Inc., USA) placed just above the aortic cannula. The electrical activity of the heart preparations
was assessed from the volume-conducted ECG as well as monophasic action potential record-
ings. Throughout the experiments, the heart preparations were kept immersed in the tempera-
ture-controlled, perfusate-filled chamber to minimize thermal loss. Aortic pressure, coronary
flow rate, ECG and ventricular monophasic action potentials were continuously monitored
using the 16-channel PowerLab system (ADInstruments, Oxford, UK).
Electrophysiological recordings
In order to slow the intrinsic beating rate and enable ventricular pacing over a wide range
of diastolic intervals, both atria were removed and the atrioventricular (AV) node was
crushed mechanically with forceps prior to taking electrophysiological recordings. Mono-
phasic action potentials (MAP) [18] were recorded at the left ventricular (LV) and right
ventricular (RV) epicardial base (Fig 1) using J-shaped, spring-loaded pressure contact
Fig 1. Representative monophasic action potential recordings obtained upon measuring the effective refractory period.
Panel A shows monophasic action potentials (MAP) recorded from the left ventricular (LV) and the right ventricular (RV) epicardium
upon extrasystolic stimulations applied at a basic drive cycle length of 550 ms. The moments of S1 and S2 application are shown by
vertical dotted lines. The numbers (ms) shown indicate the effective refractory period (last beat in LV MAP) and the LV-to-RV
conduction time (second beat in RV MAP). Panel B illustrates location of the LV and RV MAP recording electrodes (open circles), and
the LV stimulating (St) electrode (filled circle).
doi:10.1371/journal.pone.0172683.g001
Na+ channel blockers and excitation wavelength
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electrodes (Hugo Sachs Electronik-Harvard Apparatus GmbH, March-Hugstetten, Ger-
many). The MAP duration was measured at 90% repolarization (APD90). Electrical stimula-
tions were applied at LV epicardium close to the MAP recording site using 2 ms rectangular
pulses of twice diastolic threshold current generated by a programmable stimulator (Hugo
Sachs Electronik-Harvard Apparatus GmbH, March-Hugstetten, Germany). Epicardial pac-
ing thresholds were measured both at baseline and upon drug infusion, and the stimulating
current strength was adjusted appropriately whenever necessary.
The LV-to-RV conduction time during LV pacing was determined as the delay between the
fastest upstroke of the LV action potential and the RV MAP recording. The effective refractory
period was measured by application of the premature extrastimulus (S2) after a train of 20 reg-
ular (S1) pulses. The S1-S2 coupling stimulation interval was reduced from 210 ms in 5–10 ms
steps until getting no capture. The ERP was defined as the longest S1-S2 interval producing no
extrasystolic response (Fig 1). The relative excitation wavelength (EW) was calculated as a
ratio of ERP and the LV-to-RV conduction time, as described previously [19–22], and pre-
sented throughout the paper as a dimensionless numerical variable.
Electrical restitution
During extrasystolic stimulations, ventricular conduction times, ERPs, and the corresponding
relative exctitation wavelength values were determined over a wide range of S1-S1 intervals in a
basic drive train. The measurements were started with a S1-S1 cycle length of 550 ms (the lon-
gest pacing interval producing no ventricular escape beats), which was then reduced to 500
ms, followed by further reductions in steps of 20 ms over an S1-S1 range from 500 to 200 ms,
and by 5–10 ms reductions from 200 ms down to pacing intervals (about 170 ms) producing
2:1 conduction block. In AV-blocked preparations, the minimum pacing intervals achieved
with this protocol remain significantly greater than the threshold value of S1-S1 interval for
inducing repolarization alternans (90–100 ms in intact guinea-pig heart upon normokalemic
perfusion) [23], meaning that the whole dynamic pacing protocol could have been completed
without inducing electrical instability.
Once the electrical stimulations were performed, appropriate diastolic intervals (DI) were
calculated as a difference between the S1-S1 cycle length and the ERP measured. The electrical
restitution was assessed by plotting ERPs, conduction times, and the relative excitation wave-
length as a function of the preceding DI [24]. The ERP and EW restitution curves were fitted
using double-exponential function: y = y0 + A1exp
(-DI/τ1) + A2exp
(-DI/τ2), where y represents
ERP or EW, y0 is a free-fitting variable, A1 and A2 are the amplitudes, and τ1 and τ2 are the
time constants of the fast (A1 and τ1) and slow (A2 and τ2) exponential components obtained
by a least squares fit. The curve fitting was performed using Igor Pro 6.0 software (Wave-
Metrics, Inc., Portland, OR, USA). The exponential curves were then differentiated to deter-
mine the maximum slope of electrical restitution. With ventricular conduction assessments,
the restitution plot fitting and differentiating were not applied owing to the flat basal relation-
ships between the LV-to-RV conduction times and the preceding diastolic intervals (Fig 2).
Drug infusions
In total, 32 isolated, perfused heart preparations were used in this study, in order to examine
electrophysiological effects produced by flecainide, quinidine, lidocaine, and mexiletine (8
experiments in each group). For precise dosing, drug infusions were performed at a rate of 0.3
ml/min using a calibrated infusion pump, while perfusing the hearts with protein-free saline
solution at a constant coronary flow rate (see above). Flecainide (1.5 μM), quinidine (5 μM),
lidocaine (5 μM), and mexiletine (5 μM) (all from Sigma-Aldrich, Germany) were infused over
Na+ channel blockers and excitation wavelength
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30 min, at concentrations close to the maximum free (i.e. protein-unbound) therapeutic
plasma levels determined in cardiac patients [6, 25–30] (S1 Table).
Data analysis
Data are expressed as mean ± standard error of the mean. One-way ANOVA was used for
multiple comparisons, and paired t-tests were used to compare two data sets. P values less than
0.05 were considered to be significant. Original data points are given in the S1 File.
Results
Baseline characteristics of electrical restitution in perfused heart
preparations
Representative recordings of ventricular monophasic action potentials and assessments of ERP
are shown in Fig 1, and the basal ERP restitution curves obtained in each study group are
shown in Figs 3–6 (panel A, open squares). In 32 experiments, the S1-S1 reduction in a train of
regular pulses from 550 ms to 169±2 ms (the minimum cycle length with 1:1 LV capture) was
associated with shortening of the diastolic interval from 384±3 ms to 39±2 ms. and exponential
Fig 2. Effects of flecainide (panel A), quinidine (panel B), lidocaine /panel C), and mexiletine (panel D) on LV-to-RV conduction
time. Conduction times were determined in the last beat of a train of 20 regular (S1) pulses during ERP measurements at baseline and
following drug infusion. The S1-S1 interval in a train was progressively reduced from 550 ms to 170 ms, as described in Methods, to generate
a range of diastolic intervals (DI) from about 380 ms to 40 ms. The heart was allowed to beat spontaneously for 5–10 s in between successive
stimulations.
doi:10.1371/journal.pone.0172683.g002
Na+ channel blockers and excitation wavelength
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reduction of ERP from 166±2 ms to 130±2 ms. The steepness of the ERP restitution curve was
progressively increasing upon a reduction of the diastolic interval (panel C in Figs 3–6), with
the averaged maximum ERP restitution slope value attained being 0.80±0.03. The LV-to-RV
Fig 3. Effects of flecainide on the restitution of effective refractory period and excitation wavelength. Effective refractory periods
(ERP) (panel A) and the relative excitation wavelength (EW) values (panel B) were determined at baseline and after drug infusion and plotted
as a function of preceding diastolic interval (DI). The restitution curves were differentiated in order to assess changes in the restitution slope
over the range of DIs used (panels C and D). Mean values of the maximum restitution slope (panels E and F) were calculated using individual
measurements from each experiment. *P<0.05 vs. basal value (in panels E and F). The same figure design is used in Figs 4–6.
doi:10.1371/journal.pone.0172683.g003
Na+ channel blockers and excitation wavelength
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conduction time values (~12–13 ms) determined prior to drug infusions were relatively con-
stant over a wide range of the diastolic intervals (Fig 2, open squares in panels A-D). Therefore,
the restitution of the excitation wavelength in this setting (panels B and D in Figs 3–6) was
entirely determined by the rate-dependent changes in ERP, and showed a similar time course.
ANOVA revealed no between group differences in basal ERP and conduction times, as well as
the maximum slopes of ERP restitution and excitation wavelength restitution.
Fig 4. Effects of quinidine on the restitution of effective refractory period and excitation wavelength.
doi:10.1371/journal.pone.0172683.g004
Na+ channel blockers and excitation wavelength
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Flecainide and quinidine
ERP restitution. Flecainide and quinidine prolonged epicardial action potential duration
(Table 1), and increased ERP over a wide range of stimulation intervals, thereby causing the
ERP restitution curve to shift upwards (panel A in Figs 3 and 4). With both agents, the relative
Fig 5. Effects of lidocaine on the restitution of effective refractory period and excitation wavelength.
doi:10.1371/journal.pone.0172683.g005
Na+ channel blockers and excitation wavelength
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increase in ERP was found to be greater at the minimum (~40 ms) as compared to the maxi-
mum (~380 ms) diastolic intervals. For example, at the minimum DI, the ERP was increased
upon flecainide infusion by 21% (from 131±2 ms to 158±3 ms), whereas at the maximum
DI, the ERP was increased only by 8% (from 169±3 ms to 182±3 ms). With quinidine, the
ERPs determined at the minimum vs. the maximum DI were increased by 16% and 10%,
Fig 6. Effects of mexiletine on the restitution of effective refractory period and excitation wavelength.
doi:10.1371/journal.pone.0172683.g006
Na+ channel blockers and excitation wavelength
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respectively (Minimum DI: ERP prolonged from 128±3 ms to 148±3 ms; Maximum DI: ERP
prolonged from 166±3 ms to 183±4 ms).
The use-dependent ERP prolongation contributed to flattening of the ERP restitution curve
by flecainide (Fig 3, panels A, C and E) and quinidine (Fig 4, panels A, C and E), as evidenced
by reduction in the ERP restitution slope value at short (less than 100 ms) diastolic intervals,
compared to basal values. The maximum ERP restitution slope was significantly decreased by
flecainide (Basal: 0.84±0.07; Flecainide: 0.36±0.05; P = 0.003) and quinidine (Basal: 0.81±0.08;
Quinidine: 0.40±0.05; P = 0.01)
Ventricular conduction. Flecainide and quinidine increased QRS duration on ECG
(Table 1), and slowed the LV-to-RV conduction (Fig 2, panels A and B). With both agents, an
increase in ventricular conduction time was found to be greater at the minimum as compared
to the maximum diastolic intervals. For example, at the minimum DI, the LV-to-RV conduc-
tion time was prolonged upon flecainide infusion by 75% (from 12±1 ms to 21±1 ms), whereas
at the maximum DI, it was increased only by 33% (from 12±1 ms to 16±1 ms). With quinidine,
the LV-to-RV conduction times determined at the minimum vs. the maximum DI were in-
creased by 53% and 30%, respectively (Minimum DI: conduction time prolonged from 13±1
ms to 20±1 ms; Maximum DI: conduction time prolonged from 13±1 ms to 17±1 ms).
Excitation wavelength. In assessments of the relative excitation wavelength upon infusion
of flecainide and quinidine, drug-induced conduction slowing was found to prevail over effects
related to increased ERP. Indeed, despite prolonged refractoriness, the excitation wavelength
values were reduced over a wide range of diastolic intervals by flecainide and quinidine (panel
B in Figs 3 and 4). Importantly, owing to the use-dependent nature of conduction slowing by
the Na+ channel blockers, the relative reduction in the excitation wavelength was larger at the
minimum as compared to the maximum diastolic intervals. For example, at the minimum DI,
the EW was reduced upon flecainide infusion by 28% (from 10.9±0.6 to 7.8±0.4), whereas at
the maximum DI, the EW was reduced only by 18% (from 14.5±0.8 to 11.8±0.8). With quini-
dine, the EWs determined at the minimum vs. the maximum DI were decreased by 28% and
15%, respectively (Minimum DI: EW decreased from 10.2±0.7 ms to 7.3±0.5; Maximum DI:
EW decreased from 13.0±0.9 to 11.0±0.9).
A greater reduction in EW at the minimum vs. the maximum DIs translated to the steepen-
ing of EW restitution curve by flecainide (Fig 3, panels B, D and F) and quinidine (Fig 4, panels
B, D and F). The maximum EW restitution slope was significantly increased by flecainide
(Basal: 0.060±0.006; Flecainide: 0.090±0.008; P = 0.001) and quinidine (Basal: 0.061±0.006;
Quinidine: 0.089±0.008; P = 0.01).
Table 1. Effects of Na+ channel blockers on ventricular APD90 and QRS duration.
Flecainide Quinidine Lidocaine Mexiletine
LV APD90
Basal 161±2 164±3 163±2 162±3
Drug-induced 180±3* 181±3* 162±3 167±3
RV APD90
Basal 165±2 169±3 167±2 168±3
Drug-induced 177±2* 184±3* 164±4 166±4
QRS
Basal 28±2 29±2 28±1 26±2
Drug-induced 35±3* 35±2* 28±2 27±2
APD90 and QRS values (both in ms) were determined during LV pacing at S1-S1 = 550 ms.
*P<0.05 vs. basal.
doi:10.1371/journal.pone.0172683.t001
Na+ channel blockers and excitation wavelength
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Lidocaine and mexiletine
ERP restitution. Lidocaine and mexiletine had no effect on epicardial action potential
duration (Table 1), but moderately increased ERP (panel A in Figs 5 and 6), with effect being
more pronounced at the minimum compared to the maximum diastolic intervals. With lido-
caine, the ERP determined at the minimum DI was increased by 15% (from 130±2 ms to 149
±3 ms; P = 0.0002), whereas at the maximum DI, the ERP was increased only by 6% (from 166
±3 ms to 176±3 ms; P = 0.01). With mexiletine, the ERPs determined at the minimum vs. the
maximum DI were increased by 11% and 4%, respectively (Minimum DI: ERP prolonged
from 127±2 ms to 141±3 ms, P = 0.004; Maximum DI: ERP prolonged from 163±3 ms to 170
±3 ms, P = 0.02).
The use-dependent ERP prolongation contributed to flattening of the ERP restitution curve
by lidocaine (Fig 5, panels A, C and E) and mexiletine (Fig 6, panels A, C and E). The maxi-
mum ERP restitution slope was significantly decreased by lidocaine (Basal: 0.81±0.08; Lido-
caine: 0.48±0.05; P = 0.004) and mexiletine (Basal: 0.75±0.08; Mexiletine: 0.39±0.04; P = 0.01).
Ventricular conduction. Lidocaine and mexiletine had no effect on either QRS duration
on ECG (Table 1) or the LV-to-RV conduction delay assessed at variable stimulation intervals
(panels C and D in Fig 2).
Excitation wavelength. In the absence of significant conduction slowing, the rate-depen-
dent changes in the relative excitation wavelength upon infusion of lidocaine and mexiletine
were largely determined by drug effects on ERP. Similar to ERP restitution, the EW restitution
curve was flattened at short diastolic intervals by both agents (panels B, D and F in Figs 5 and
6). The maximum EW restitution slope was reduced by lidocaine (Basal: 0.066±0.007; Lido-
caine: 0.022±0.004; P = 0.002) and mexiletine (Basal: 0.070±0.007; Mexiletine: 0.025±0.003;
P = 0.01)
Discussion
Main findings
This study shows that the interplay between drug effects on ventricular refractoriness and con-
duction may result in differential changes in the rate adaptation of the excitation wavelength
upon administration of class Ia (quinidine) and Ic (flecainide) compared to class Ib (lidocaine
and mexiletine) Na+ channel blockers. Consistent with antiarrhythmic tendency, all the agents
were found to use-dependently prolong ventricular refractoriness, thus flattening the ERP res-
titution curve. Nevertheless, when assessing the excitation wavelength dynamics, with flecai-
nide and quinidine, the beneficial changes in ERP were reversed owing to the prominent LV-
to-RV conduction slowing at short diastolic intervals, thereby leading to significantly increased
steepness of the excitation wavelength restitution. In contrast, with lidocaine and mexiletine,
ventricular conduction times were not changed, and therefore the maximum slope of the exci-
tation wavelength restitution was reduced, as expected from the flattened ERP rate adaptation.
Contrasting effects of the Na+ channel blockers on the restitution of the excitation wavelength
can be considered as the contributing mechanism to the previously reported differences in
clinical safety profile between class Ia and Ic vs. class Ib agents.
Na+ channel blocker effects on ventricular refractoriness, conduction,
and arrhythmic susceptibility
Class I antiarrhythmic agents can delay the recovery of INa from inactivation during ventricu-
lar repolarization, an effect which postpones the recurrence of excitability and therefore con-
tributes to the prolonged ERP. While an increase in ERP appears to represent the “class effect”
Na+ channel blockers and excitation wavelength
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of the INa blockers, these agents nevertheless exhibit markedly variable efficacy in modulating
ventricular conduction, which can be determined by the kinetics of drug binding to the Na+
channel. For example, lidocaine and mexiletine preferentially bind to the Na+ channels in the
inactivated state (i.e., during the plateau phase), and equally reduce both the number of open
channel events and the average duration of opening for each event [31–33]. These agents
exhibit fast dissociation rates from their binding site in INa channel [8–9], meaning that drug-
induced INa block persists during ventricular action potential, but then rapidly (within 0.09–
0.18 s [34–35]) dissipates in early diastole. Consequently, class Ib agents at therapeutic concen-
trations produce only little or no change in ventricular conduction, at least in non-ischemic
hearts [36–37]. In contrast, flecainide and quinidine preferentially bind to the open Na+ chan-
nels (i.e., during depolarization phase), and exhibit much slower offset kinetics. The time con-
stant of INa recovery was reported to be 3–8 s for quinidine [35, 38], and 11–15 s for flecainide
[35, 39]. As these values by far exceed diastolic intervals over the range of clinically relevant
heart rates, the drug-induced INa block may persist and cumulate over successive cardiac beats,
leading to the profound conduction slowing. Accordingly, in the present study, flecainide and
quinidine were found to both significantly increase the QRS duration on ECG (Table 1) and
use-dependently prolong the LV-to-RV conduction time (panels A and B in Fig 2), whereas
lidocaine and mexiletine had no significant effect on ventricular conduction (panels C and D
in Fig 2).
In studies on VT inducibility by programmed stimulation, the propensity of class I agents
to suppress arrhythmia has been shown to be determined by the relations between drug effects
on ERP and those on ventricular conduction [40–42]. A greater ERP prolongation at the stim-
ulation site in the presence of minimal conduction slowing on drug administration tends to
abolish re-entry and suppress the arrhythmia in patients responding to therapy, whereas more
prominent conduction slowing and a lesser increase in ERP was considered to stabilize a re-
entrant circuit and favor arrhythmia in patients with still inducible VT (i.e., in non-respond-
ers). These clinical findings are in line with the wavelength theory which prescribes that re-
entry can be perpetuated in cardiac tissue only when the excitation wavelength, a product of
ERP and conduction velocity, fits the size of the available anatomic pathway for impulse con-
duction [43–44]. Drug-induced reduction in the excitation wavelength, via effects on either
ERP or ventricular conduction, or both, would allow the re-entry to sustain in a smaller mass
of cardiac tissue, indicating a proarrhythmic effect. In contrast, an increase in the excitation
wavelength can eliminate the chance to establish the re-entrant circuit in the available myocar-
dium, indicating an antiarrhythmic action.
Although these studies can explain the mechanism for antiarrhythmic vs. proarrhythmic
effects produced by class I agents at a fixed heart rate, they offer no insight into the role played
by the dynamic changes in the excitation wavelength in drug-induced arrhythmogenicity.
The wavelength is highly sensitive to the variations of the cardiac beating interval, and the
dynamics of its rate adaptation is thought to be critical for the initiation and maintenance of
reentry, and can be a factor which determines the success or failure of antiarrhythmic therapies
[45–47]. With this line of reasoning, the arrhythmic safety profile of the INa blockers can be
considered to be strongly influenced by drug effects on the kinetics of excitation wavelength
restitution.
Electrical restitution
At increased cardiac activation rates, ventricular repolarization is shortened upon a progres-
sive reduction of the preceding diastolic interval, an effect attributed to incomplete deactiva-
tion of the outward K+ currents, IKr and IKs (the rapid and the slow components of the delayed
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rectifier, respectively). Rapid S1-S1 pacing also increases intracellular Na
+ levels, which stimu-
late the reversed mode of the Na+-Ca2+ exchange and Na+-K+ pump, thus contributing to
APD shortening. In addition, APD reduction in tachycardia can be partly attributed to faster
inactivation of ICa in cardiac myocytes caused by elevated cytosolic Ca2+ levels [48]. With elec-
trical restitution analysis based on plotting action potential duration as a function of the DI,
the steep slope of APD rate adaptation has been shown to facilitate VF by inducing APD and
Ca2+ transient alternans [21, 48–50], whereas flattening the electrical restitution can increase
stability of the activation wavefront and prevent arrhythmia [14–15].
It should be noted, however, that the slope of the electrical restitution curve is not the only
determinant of proarrhythmic tendency. The stability of the excitation wavefront can also be
influenced by conduction velocity restitution, short-term cardiac memory, electrotonic effects,
and Ca2+ cycling [15, 51–52]. These factors may dynamically interact with each other, thereby
modifying arrhythmic substrate. For example, both electrotonic and memory effects can sup-
press arrhythmogenic APD alternans, despite a steep electrical restitution curve [52]. These
complexities should be considered while interpreting Na+ channel blockers effects on electrical
restitution. In particular, in the present study, both flecainide and quinidine were found to
reduce the slope of the ERP restitution curve (panels A, C and E in Figs 3 and 4), which does
not corroborate the proarrhythmic profile of these agents, as evidenced from clinical studies
[3–5]. This apparent controversy raises a possibility that beneficial effects related to flattening
ERP restitution can be significantly eliminated, or even reversed to proarrhythmia, owing to
the drug-induced conduction slowing which translates to adverse modifications of the excita-
tion wavelength.
Na+ channel blockers and the excitation wavelength
Previous studies addressed changes in APD90 rate adaptation upon administration of various
Na+ channel blockers [53–58]. However, with class I agents, the excitation wavelength restitu-
tion is likely to be more reliable than the APD90 restitution in assessments of the proarrhyth-
mic tendency. First, during Na+ channel blocker therapy, changes in ERP may dissociate from
those in APD90, which can be exemplified by the phenomenon of drug-induced post-repolari-
zation refractoriness [19]. This presumes that modifications in APD90 rate adaptation by Na
+
channel blocker may not necessarily be equivalent to those in ERP restitution. Second, drug-
induced conduction slowing may impair the rate adaptation of the excitation wavelength
and promote cardiac electrical instability, an effect which can be overlooked when assessments
of arrhythmogenic tendency are solely based on measuring the APD90 restitution slope.
Finally, the important advantage of the excitation wavelength restitution analysis is that it can
give a key to discriminating Na+ channel blockers with antiarrhythmic and proarrhyrhmic
profile of action based on the balance between the relative drug effects on ERP and ventricular
conduction.
Importantly, clinical studies demonstrate that arrhythmogenic responses to Na+ channel
blockers are often precipitated upon heart rate acceleration during exercise testing [59], thus
raising a possibility that drug-induced abnormalities in the restitution of ventricular conduc-
tion and/or refractoriness, and the resulting changes in the excitation wavelength, may play a
role in creating arrhythmic substrate. The present study offers a more detailed insight into the
nature of this mechanism. First, because flecainide and quinidine produce a greater relative
increase in the LV-to-RV conduction time compared to ERP, they reduce the absolute value of
the excitation wavelength determined at a given diastolic interval (panel B in Figs 3 and 4).
This tendency may potentially allow the re-entry to occur around the LV-to-RV circumfer-
ence, and initiate tachyarrhythmia. Second, owing to the more pronounced conduction
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slowing at the short as compared to the long diastolic intervals (panels A and B in Fig 2), both
flecainide and quinidine can increase the maximum slope of the excitation wavelength restitu-
tion curve (panels D and F in Figs 3 and 4). This means that for a given reduction in diastolic
interval upon heart rate acceleration, the decrement in the excitation wavelength value is sig-
nificantly greater in the presence of flecainide and quinidine. As a result, at the shortest DI, the
relative EW was decreased by about 30% from its basal value (panel B in Figs 3 and 4) with
both agents. This tendency may potentially lead to EW reduction below the minimal value
necessary for stable propagation of the activation front [60]. These arguments suggest that a
critical EW reduction, as facilitated by a steep EW restitution, is likely to be the most important
determinant of proarrhythmia upon infusion of flecainide and quinidine.
Limitations
Effects of Na+ channel blockers on ventricular refractoriness and conduction assessed in
this study in normal hearts may not necessarily be identical to those induced in diseased myo-
cardium. For example, depolarized ischemic cardiac cells may develop voltage-dependent
inactivation of the Na+ channels, which would further accentuate depression of myocardial
excitability by class I agents, and set a stage for proarrhythmia.
In the present study, the electrical restitution was analyzed by plotting ERP, ventricular
conduction time, and the relative EW values vs. preceding diastolic interval. The strength of
these assessments can be further increased by incorporating cardiac memory effects (e.g., via
analysis of the electrical restitution portrait [51]), based on the premise that APD in a given
cardiac beat is influenced by multiple preceding DIs. Whether cardiac memory effects can be
modified by Na+ channel blockers, is uncertain, and warrants further studies.
Because ventricular conduction time is the inverse correlate of conduction velocity, the
ratio between the effective refractory period and conduction time can be used as a measure of
the excitation wavelength [19–22]. The direct measurements of conduction velocity rather
than conduction times would likely to allow more precise evaluation of the excitation wave-
length, but this would require using the multielectrode APD mapping in order to define the
impulse conduction pathway, which was not performed in this study. It is noteworthy, how-
ever, that excitation wavelength assessments based on measuring ventricular conduction times
in perfused hearts from different animal species were carefully validated in previous studies,
and found to be reliable in detecting changes in arrhythmic tendency in the setting of hypoka-
lemia [22], and antiarrhythmic drug infusion [19, 21]. Furthermore, in the clinical studies, the
cardiac wavelength is always assessed indirectly, i.e. by correcting the ERP for QRS duration
[40–41], or the local conduction delay [20], suggesting the relevance of the aforementioned
approach.
In contrast to lidocaine and mexiletine, selective INa blockers, flecainide and quinidine can
also inhibit outward K+ currents, such as IKr [61–62], which could have contributed to the pro-
longation of APD90 observed upon infusion of these agents in this study (Table 1). Excessive
APD90 prolongation by flecainide and quinidine, in turn, can potentially promote repolariza-
tion abnormalities, including increased spatial repolarization gradients and impaired activa-
tion-to-repolarization coupling [55–56, 63]. Therefore, the mechanism by which arrhythmia
can be facilitated by class Ia and Ic, as opposed to class Ib agents, is likely to be multifactorial,
and not limited to their contrasting effects on the excitation wavelength dynamics.
Finally, it is worth mentioning that although class Ib Na+ channel blockers are regarded as
safe agents, they are not widely used in contemporary cardiology practice compared to other
antiarrhythmics (e.g. amiodarone). Lidocaine is not available orally, and mexiletine, its oral
congener, is no longer marketed. Although lidocaine was proved to reduce the risk of VF in
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acute myocardial infarction [7], it does not improve mortality and may produce asystole in
patients with damaged cardiac conduction system [64]. Prophylactic lidocaine is therefore no
longer recommended in this setting.
Conclusions
The steepness of the rate adaptation of the excitation wavelength in perfused guinea-pig hearts
is increased by flecainide and quinidine, whereas lidocaine and mexiletine flatten the excita-
tion wavelength restitution. These contrasting changes are likely to contribute to the differ-
ences in arrhythmic safety profile previously reported for class Ia and Ic vs. class Ib Na+
channel blockers in clinical studies.
Supporting information
S1 File. Original statistical data points.
(XLSX)
S1 Table. Therapeutic plasma levels of flecainide, quinidine, lidocaine and mexiletine and
the drug concentrations used in the present study.
(DOC)
Acknowledgments
The author appreciates financial support from the Department of Health Science and Technol-
ogy, University of Aalborg.
Author Contributions
Conceptualization: OO.
Data curation: OO.
Formal analysis: OO.
Investigation: OO.
Methodology: OO.
Project administration: OO.
Resources: OO.
Validation: OO.
Visualization: OO.
Writing – original draft: OO.
Writing – review & editing: OO.
References
1. Roden DM, Anderson ME (2006). Proarrhythmia. Handb Exp Pharmacol 171:73–97.
2. Frommeyer G, Eckardt L (2016). Drug-induced proarrhythmia: risk factors and electrophysiological
mechanisms. Nat Rev Cardiol 13: 36–47. doi: 10.1038/nrcardio.2015.110 PMID: 26194552
3. The CAST Investigators (1989). Preliminary report: effect of encainide and flecainide on mortality in a
randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med 321: 406–412.
doi: 10.1056/NEJM198908103210629 PMID: 2473403
Na+ channel blockers and excitation wavelength
PLOS ONE | DOI:10.1371/journal.pone.0172683 February 23, 2017 15 / 18
4. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC (1990). Efficacy and safety of quinidine ther-
apy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.
Circulation 82: 1106–1116. PMID: 2144796
5. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG (1992). Antiarrhythmic drug
therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investiga-
tors. J Am Col Cardiol 20: 527–532.
6. Woosley RL, Wang T, Stone W, Siddoway L, Thompson K, Duff HJ, et al. (1984). Pharmacology,
electrophysiology, and pharmacokinetics of mexiletine. Am Heart J 107: 1058–1065. PMID: 6326558
7. Wyman MG, Wyman RM, Cannom DS, Criley JM (2004). Prevention of primary fibrillation in acute myo-
cardial infarction with prophylactic lidocaine. Am J Cardiol 94: 545–551. doi: 10.1016/j.amjcard.2004.
05.014 PMID: 15342281
8. Tamargo J, Valenzuela C, Delpon E (1992). New insights into the pharmacology of sodium channel
blockers. Eur Heart J 13 Suppl F: 2–13.
9. Glaaser IW, Clancy CE (2006). Cardiac Na+ channels as therapeutic targets for antiarrhythmic agents.
Handb Exp Pharmacol 171: 99–121.
10. Panidis IP, Morganroth J (1983). Sudden death in hospitalized patients: cardiac rhythm disturbances
detected by ambulatory electrocardiographic monitoring. J Am Coll Cardiol 2: 798–805. PMID:
6630760
11. Milner PG, Platia EV, Reid PR, Griffith LSC (1985). Ambulatory electrocardiographic recordings at the
time of fatal cardiac arrest. Am J Cardiol 56: 588–592. PMID: 4050692
12. Kim YH, Yashima M, Wu TJ, Doshi R, Chen PS, Karagueuzian HS (1999). Mechanism of procaina-
mide-induced prevention of spontaneous wave break during ventricular fibrillation. Circulation 100:
666–674. PMID: 10441106
13. Harada M, Tsuji Y, Ishiguro YS, Takanari H, Okuno Y, Inden Y, et al. (2011). Rate-dependent shorten-
ing of action potential duration increases ventricular vulnerability in failing rabbit heart. Am J Physiol
Heart Circ Physiol 300: H565–573. doi: 10.1152/ajpheart.00209.2010 PMID: 21148762
14. Weiss JN, Garfinkel A, Karagueuzian HS, Qu Z, Chen PS (1999). Chaos and the transition to ventricular
fibrillation. A new approach to antiarrhythmic drug evaluation. Circulation 99: 2819–2826. PMID:
10351978
15. Weiss JN, Qu Z, Chen PS, Lin SF, Karagueuzian HS, Hayashi H, et al. (2005). The dynamics of cardiac
fibrillation. Circulation 112: 1232–1240. doi: 10.1161/CIRCULATIONAHA.104.529545 PMID:
16116073
16. Osadchii O, Norton G, Deftereos D, Woodiwiss A (2007). Rat strain-related differences in myocardial
adrenergic tone and the impact on cardiac fibrosis, adrenergic responsiveness and myocardial structure
and function. Pharmacol Res 55: 287–294. doi: 10.1016/j.phrs.2006.12.005 PMID: 17257851
17. Soltysinska E, Thiele S, Olesen SP, Osadchii OE (2011). Chronic sympathetic activation promotes
downregulation of β-adrenoceptor-mediated effects in the guinea-pig heart independently of structural
remodeling and systolic dysfunction. Pflugers Arch 462: 529–543. doi: 10.1007/s00424-011-1005-7
PMID: 21811789
18. Franz MR (1999). Current status of monophasic action potential recording: theories, measurements
and interpretations. Cardiovasc Res 41: 25–40. PMID: 10325951
19. Kirchhof PF, Fabritz CL, Franz MR (1998). Postrepolarization refractoriness versus conduction slowing
caused by class I antiarrhythmic drugs. Antiarrhythmic and proarrhythmic effects. Circulation 97:
2567–2574. PMID: 9657478
20. Minami T, Isomoto S, Nakao K, Komiya N, Fukae S, Centurion OA, et al. (2004). Effects of intravenous
nifekalant, a class III antiarrhythmic drug, on atrial vulnerability parameters in patients with paroxysmal
atrial fibrillation. Pacing Clin Electrophysiol 27: 212–217. PMID: 14764172
21. Matthews GDK, Guzadhur L, Sabir IN, Grace AA, Huang CLH (2013). Action potential wavelength resti-
tution predicts alternans and arrhythmia in murine Scn5a+/- hearts. J Physiol 591: 4167–4188. doi: 10.
1113/jphysiol.2013.254938 PMID: 23836691
22. Osadchii OE (2014). Impact of hypokalemia on electromechanicl window, excitation wavelength and
repolarization gradients in guinea-pig and rabbit hearts. PLoS One 9: e105599. doi: 10.1371/journal.
pone.0105599 PMID: 25141124
23. Osadchii OE (2014). Reduced intrinsic heart rate is associated with reduced arrhythmic susceptibility in
guinea-pig heart. Scand Cardiovasc J 48: 357–367. doi: 10.3109/14017431.2014.976256 PMID:
25334079
24. Osadchii OE, Larsen AP, Olesen SP (2010). Predictive value of electrical restitution in hypokalemia-
induced ventricular arrhythmogenicity. Am J Physiol Heart Circ Physiol 298: H210–H220. doi: 10.1152/
ajpheart.00695.2009 PMID: 19897712
Na+ channel blockers and excitation wavelength
PLOS ONE | DOI:10.1371/journal.pone.0172683 February 23, 2017 16 / 18
25. Conard GJ, Ober RE (1984). Metabolism of flecainide. Am J Cardiol 53: 41B–51B. PMID: 6364769
26. Kates RE, Sokoloski TD, Comstock TJ (1978). Binding of quinidine to plasma proteins in normal sub-
jects and in patients with hyperlipoproteinemias. Clin Pharmacol Ther 23: 30–35. PMID: 618708
27. Benton RE, Sale M, Flockhart DA, Woosley RL (2000). Greater quinidine-induced QTc interval pro-
longation in women. Clin Pharmacol Ther 67: 413–418. doi: 10.1067/mcp.2000.105761 PMID:
10801251
28. Collinsworth KA, Kalman SM, Harrison DC (1974). The clinical pharmacology of lidocaine as an antiar-
rhythmic drug. Circulation 50: 1217–1230. PMID: 4609637
29. Routledge PA, Barchowsky A, Bjornsson TD, Kitchell BB, Shand DG (1980). Lidocaine plasma protein
binding. Clin Pharmacol Ther 27: 347–351. PMID: 7357791
30. Pentikainen PJ, Halinen MO, Helin MJ (1983). Pharmacokinetics of oral mexiletine in patients with
acute myocardial infarction. Eur J Clin Pharmacol 25: 773–777. PMID: 6662176
31. McDonald TV, Courtney KR, Clusin WT (1989). Use-dependent block of single sodium channels by lido-
caine in guinea-pig ventricular myocytes. Biophys J 55: 1261–1266. doi: 10.1016/S0006-3495(89)
82921-2 PMID: 2548633
32. Courtney KR (1981). Comparative actions of mexiletine on sodium channels in nerve, skeletal and car-
diac muscle. Eur J Pharmacol 74: 9–18. PMID: 6274652
33. Sunami A, Fan Z, Sawanobori T, Hiraoka M (1993). Use-dependent block of Na+ currents by mexiletine
at the single channel level in guinea-pig ventricular myocytes. Br J Pharmacol 110: 183–192. PMID:
8220878
34. Grant AO, Strauss LJ, Wallace AG, Strauss HC (1980). The influence of pH on the electrophysiological
effects of lidocaine in guinea-pig ventricular myocardium. Circ Res 47: 542–550. PMID: 6773697
35. Varro A, Elharrar V, Surawicz B (1985) Frequency-dependent effects of several class I antiarrhythmic
drugs on Vmax of action potential upstroke in canine cardiac Purkinje fibers. J Cardiovasc Pharmacol 7:
482–492. PMID: 2410678
36. Bigger JT, Mandel WJ (1970). Effect of lidocaine on conduction in canine Purkinje fibers and at the ven-
tricular muscle-Purkinje fiber junction. J Pharmacol Exp Ther 172: 239–254. PMID: 5441153
37. Rosen KM, Lau SH, Weiss MB, Damato AN (1970). The effects of lidocaine on atrioventricular and intra-
ventricular conduction in man. Am J Cardiol 25: 1–5. PMID: 5413183
38. Hondeghem LM, Matsubara T (1988). Quinidine blocks cardiac sodium channels during opening and
slow inactivation in guinea-pig papillary muscle. Br J Pharmacol 93: 311–318. PMID: 2451964
39. Campbell TJ, Vaughan Williams EM (1983). Voltage- and time-dependent depression of maximum rate
of depolarization of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide
and lorcainide. Cardiovasc Res 17: 251–258. PMID: 6883400
40. Furukawa T, Rozanski JJ, Moroe K, Gosselin AJ, Lister JW (1989). Efficacy of procainamide on ventric-
ular tachycardia: relation to prolongation of refractoriness and slowing of conduction. Am Heart J 118:
702–708. PMID: 2801477
41. Kus T, Dubuc M, Lambert C, Shenasa M (1990). Efficacy of propafenone in preventing ventricular
tachycardia: inverse correlation with rate-related prolongation of conduction time. J Am Coll Cardiol 16:
1229–1237. PMID: 2229772
42. Karagounis LA, Anderson JL, Allen A, Osborn JS (1995). Electrophysiologic effects of antiarrhythmic
drug therapy in the prediction of successful suppression of induced ventricular tachycardia. Am Heart J
129: 343–349. PMID: 7832108
43. Smeets JL, Allessie MA, Lammers WJ, Bonke FI, Hollen J (1986). The wavelength of the cardiac
impulse and reentrant arrhythmias in isolated rabbit atrium. The role of heart rate, autonomic transmit-
ters, temperature, and potassium. Circ Res 58: 96–108. PMID: 3943157
44. Rensma PL, Allessie MA, Lammers WJEP, Bonke FIM, Schalij MJ (1988). Length of excitation wave
and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 62: 395–410.
PMID: 3338122
45. Girouard SD, Pastore JM, Laurita KR, Gregory KW, Rosenbaum DS (1996). Optical mapping in a new
guinea-pig model of ventricular tachycardia reveals mechanisms for multiple wavelengths in a single
reentrant circuit. Circulation 93: 603–613. PMID: 8565181
46. Girouard SD, Rosenbaum DS (2001). Role of wavelength adaptation in the initiation, maintenance, and
pharmacologic suppression of reentry. J Cardiovasc Electrophysiol 12: 697–707. PMID: 11405405
47. Hondeghem LM, Dumotier B, Traebert M (2010). Oscillations of cardiac wave length and proarrhythmia.
Naunyn-Schmiedebergs Arch Pharmacol 382: 367–376. doi: 10.1007/s00210-010-0549-y PMID:
20803191
Na+ channel blockers and excitation wavelength
PLOS ONE | DOI:10.1371/journal.pone.0172683 February 23, 2017 17 / 18
48. Goldhaber JI, Xie LH, Duong T, Motter C, Khuu K, Weiss JN (2005). Action potential duration restitution
and alternans in rabbit ventricular myocytes. The key role of intracellular calcium cycling. Circ Res 96:
459–466. doi: 10.1161/01.RES.0000156891.66893.83 PMID: 15662034
49. Chudin E, Goldhaber J, Garfinkel A, Weiss J, Kogan B (1999). Intracellular Ca2+ dynamics and the sta-
bility of ventricular tachycardia. Biophys J 77: 2930–2941. doi: 10.1016/S0006-3495(99)77126-2
PMID: 10585917
50. Clusin WT (2003). Calcium and cardiac arrhythmias: DADs, EADs, and alternans. Crit Rev Clin Lab Sci
40: 337–375. doi: 10.1080/713609356 PMID: 12892319
51. Kalb SS, Dobrovolny HM, Tolkacheva EG, Idriss SF, Krassowska W, Gauthier DJ (2004). The restitu-
tion portrait: a new method for investigating rate-dependent restitution. J Cardiovasc Electrophysiol 15:
698–709. doi: 10.1046/j.1540-8167.2004.03550.x PMID: 15175067
52. Cherry EM, Fenton FH (2004). Suppression of alternans and conduction blocks despite steep APD res-
titution: electrotonic, memory, and conduction velocity restitution effects. Am J Physiol Heart Circ Phy-
siol 286: H2332–H2341. doi: 10.1152/ajpheart.00747.2003 PMID: 14751863
53. Varro A, Nakaya Y, Elharrar V, Surawicz B (1986). Effect of antiarrhythmic drugs on the cycle length-
dependent action potential duration in dog Purkinje and ventricular muscle fibers. J Cardiovasc Pharma-
col 8: 178–185. PMID: 2419682
54. Osadchii OE (2012). Effects of ventricular pacing protocol on electrical restitution assessments in
guinea-pig heart. Exp Physiol 97: 807–821. doi: 10.1113/expphysiol.2012.065219 PMID: 22447974
55. Osadchii OE (2012). Flecainide-induced proarrhythmia is attributed to abnormal changes in repolariza-
tion and refractoriness in perfused guinea-pig heart. J Cardiovasc Pharmacol 60: 456–466. doi: 10.
1097/FJC.0b013e31826b86cf PMID: 22932706
56. Osadchii OE (2013). Quinidine elicits proarrhythmic changes in ventricular repolarization and refractori-
ness in guinea-pig. Can J Physiol Pharmacol 91: 306–315. doi: 10.1139/cjpp-2012-0379 PMID:
23627842
57. Osadchii OE (2014). Procainamide and lidocaine produce dissimilar changes in ventricular repolariza-
tion and arrhythmogenicity in guinea-pig. Fundam Clin Pharmacol 28: 382–393. doi: 10.1111/fcp.12046
PMID: 23952942
58. Morita N, Lee JH, Xie Y, Sovari A, Qu Z, Weiss JN, et al. (2011). Suppression of re-entrant and multifo-
cal ventricular fibrillation by the late sodium current blocker ranolazine. J Am Coll Cardiol 57: 366–375.
doi: 10.1016/j.jacc.2010.07.045 PMID: 21232675
59. Anastasiou-Nana MI, Anderson JL, Stewart JR, Crevey BJ, Yanowitz FG, Lutz JR, et al. (1987). Occur-
rence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide
for complex ventricular arrhythmias: a probable proarrhythmic effect. Am Heart J 113: 1071–1077.
PMID: 3107362
60. Chernyak YB, Starobin JM (1999). Characteristic and critical excitation length scales in 1-D and 2-D
simulations of re-entrant cardiac arrhythmias using simple two-variable models. Crit Rev Biomed Eng
27: 359–414. PMID: 10864284
61. Follmer CH, Cullinan CA, Colatsky TJ (1992). Differential block of cardiac delayed rectifier current by
class Ic antiarrhythmic drugs: evidence for open channel block and unblock. Cardiovasc Res 26: 1121–
1130. PMID: 1291091
62. Paul AA, Witchel HJ, Hancox JC (2002). Inhibition of the current of heterologously expressed HERG
potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J
Pharmacol 136: 717–729. doi: 10.1038/sj.bjp.0704784 PMID: 12086981
63. Osadchii OE (2014). Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in
ventricular conduction and repolarization. J Cardiovasc Pharmacol 63: 240–251. doi: 10.1097/FJC.
0000000000000041 PMID: 24220314
64. Marti-Carvajal AJ, Simancas-Racines D, Anand V, Bangdiwala S (2015). Prophylactic lidocaine for
myocardial infarction. Cochrane Database Syst Rev 8: CD008553.
Na+ channel blockers and excitation wavelength
PLOS ONE | DOI:10.1371/journal.pone.0172683 February 23, 2017 18 / 18
